# Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

> **NCT01597414** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 80 (estimated)

## Conditions studied

- Elderly Metastatic Breast Cancer Population

## Interventions

- **DRUG:** Pertuzumab + trastuzumab
- **DRUG:** Pertuzumab + trastuzumab + metronomic chemotherapy

## Key facts

- **NCT ID:** NCT01597414
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2017-03
- **Final completion:** 2022-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597414, "Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01597414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*